Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/26385705http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26385705http://www.w3.org/2000/01/rdf-schema#comment"

Introduction

C-X-C motif chemokine 10 (CXCL10) is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary lymphoid tissues, and the expression is upregulated by TNF-α, via T cell stimulation. It appears that CXCL10 and CXCL13 could play a potential role in the pathogenesis of adult-onset Still's disease (AOSD), therefore, we investigated the associations between CXCL10 and CXCL13 levels and clinical manifestations in patients with active AOSD.

Methods

Blood samples were collected from 39 active AOSD patients, 32 rheumatoid arthritis (RA) patients and 40 healthy controls (HC). Of the AOSD patients, follow-up samples were collected from 15 9.6 ± 9.2 months later. Serum levels of CXCL10 and CXCL13 were determined using enzyme-linked immunosorbent assay. CXCL10, CXCL13, and C-X-C chemokine receptor type 3 (CXCR3) expression levels in biopsy specimens obtained from 26 AOSD patients with skin rashes were investigated via immunohistochemistry.

Results

The CXCL10 levels in AOSD patients (1,031.3 ± 2,019.6 pg/mL) were higher than in RA (146.3 ± 91.4 pg/mL, p = 0.008) and HC (104.4 ± 47.9 pg/mL, p = 0.006). Also, the CXCL13 levels of AOSD patients (158.8 ± 151.2 pg/mL) were higher than those of RA (54.4 ± 61.1 pg/mL, p < 0.001) and HC (23.5 ± 18.1 pg/mL, p < 0.001). Serum CXCL10 levels correlated with ferritin and systemic scores. Serum CXCL13 levels correlated with those of hemoglobin, C-reactive protein, ferritin, and albumin, and systemic scores. In follow-up AOSD patients, the levels of CXCL10 and CXCL13 fell significantly (153.7 ± 130.1 pg/mL, p = 0.002, and 89.1 ± 117.4 pg/mL, p = 0.001, respectively). On immunohistochemistry, the percentages of inflammatory cells expressing CXCL10 ranged from 1 to 85%, CXCL13 from 1 to 72%, and CXCR3 from 2 to 65%. The percentage of CXCL10-positive inflammatory cells was higher in skin biopsy samples exhibiting mucin deposition than in those that did not (p = 0.01). CXCL13 levels were correlated with those of CD4 and CD68.

Conclusions

Serum CXCL10 and CXCL13 levels may serve as clinical markers for assessment of disease activity in AOSD. CXCL10/CXCR3 and CXCL13 may contribute to the inflammatory response, especially skin manifestations thereof, in AOSD."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.org/dc/terms/identifier"doi:10.1186/s13075-015-0773-4"xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Han J.H."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Kim H.A."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Yim H."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Jung J.Y."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Nam J.Y."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Kwon J.E."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/author"Suh C.H."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/name"Arthritis Res Ther"xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/pages"260"xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/title"Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease."xsd:string
http://purl.uniprot.org/citations/26385705http://purl.uniprot.org/core/volume"17"xsd:string
http://purl.uniprot.org/citations/26385705http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/26385705
http://purl.uniprot.org/citations/26385705http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/26385705
http://purl.uniprot.org/uniprot/#_O43927-mappedCitation-26385705http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26385705
http://purl.uniprot.org/uniprot/#_Q53X90-mappedCitation-26385705http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26385705
http://purl.uniprot.org/uniprot/#_P02778-mappedCitation-26385705http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26385705
http://purl.uniprot.org/uniprot/O43927http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/26385705
http://purl.uniprot.org/uniprot/Q53X90http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/26385705
http://purl.uniprot.org/uniprot/P02778http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/26385705